Starling Oncology, Inc. (DFPH)
DFPH is quoted over the counter, not listed on an exchange. Starling Oncology, Inc. files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | DFPH, quoted over the counter |
| SEC CIK | 0001799191 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Services-Offices & Clinics of Doctors of Medicine |
| Business address | Cerritos, CA |
| Incorporated in | DE |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "In connection with the preparation of the condensed consolidated financial statements as of September 30, 2026, the Company conducted an evaluation as to whether there were conditions and events, considered in the aggregate, which raised substantial doubt as to its ability to continue as a going concern within one year after the date of the issuance of such financial statements." | 10-Q 2026-11-06 |
| Cash and burn | $36.9M cash; operating cash flow $5.8M a quarter. | Report 2026-09-30 |
| Shares outstanding | 101,991,024 (2026-11-03); 98,381,340 a year earlier; 73,748,979 three years earlier. | Cover page 2026-11-03 |
| Reverse splits, 3 years | 1; latest on 2025-03-25 | Source 2025-03-25 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-11-13 |
| Auditor | BDO USA, P.C., Costa Mesa, California, United States | PCAOB Form AP 2026-03-13 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $2.7M, sold $2.8M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $169.8M | -$15.7M | $10.1M | $36.9M | $72.5M | $620.4M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $161.3M | -$9.8M | $11.9M | $41.1M | $79.9M | $587.2M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $147.4M | -$2.5M | -$2.2M | $30.3M | $78.6M | $545.8M | 10-Q 2026-05-07 |
| Q4 2025 2025-12-31 | $142.0M | -$7.5M | $3.2M | $33.6M | $77.4M | $502.7M | 10-K 2026-03-12 |
| Q3 2025 2025-09-30 | $136.6M | -$16.5M | -$12.6M | $27.7M | $76.2M | $461.0M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $119.8M | -$17.0M | -$10.2M | $30.3M | $75.0M | $424.4M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $104.4M | -$19.6M | -$5.0M | $39.7M | $73.9M | $403.2M | 10-Q 2026-05-07 |
| Q4 2024 2024-12-31 | $100.3M | -$13.2M | $4.0M | $49.7M | $93.1M | $393.4M | 10-K 2026-03-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-08-13 |
| Latest annual report | 10-K | 2026-03-12 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K/A | 2026-11-12 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 552 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier